Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Clin Cancer Res. 2017 Jan 13;23(13):3442–3452. doi: 10.1158/1078-0432.CCR-16-1815

Figure 1.

Figure 1

STXBP4 expression is correlated with p63 expression and poor prognosis in lung SCC. (A) Representative immunohistochemical staining of a lung SCC. STXBP4 immunostaining demonstrates a nuclear and cytoplasmic pattern with a score of 5. Scale bars are 200 μm. (B, C) Kaplan-Meier analysis of Overall Survival (OS) and Progression Free Survival (PFS) defined according to STXBP4 expression. A statistically significant difference in OS and PFS was observed between the STXBP4-positive patients and those with low STXBP4 expression [OS, p = 0.0056(A); PFS, p = 0.0068 (B)]. P-values were obtained by log-rank test. (D) Spearman’s rank correlation was performed based on the expression levels of STXBP4 and ΔNp63.